In today’s briefing:
- EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades- China Bouncing Back
- Index Rebalance & ETF Flow Recap: HSCI, GDXJ, KRX New Deal, AMFI, Amman Mineral, Infratil
- ECM Weekly (11th June 2023) – Alibaba, Tencent, PDD, Redox, Amman, Kotak, Infratil, Skymark
- China Healthcare Weekly (Jun.9) – Pediatric TCM New Policy, Long-Term Money Dislikes A-Share, Clover
- (Mostly) Asia-Pac Weekly Risk Arb Wrap: ENM, Estia Health, Yitai Coal, and Challenger Technologies
EQD | Volatility Update: Weekly Review of Vol Changes and Best Trades- China Bouncing Back
- Weekly summary of vol changes and moves across Global Markets
- Analysing ATM volatility and skew changes over the last 5 days
- We suggest a few trades to take advantage of the implied vol surfaces
Index Rebalance & ETF Flow Recap: HSCI, GDXJ, KRX New Deal, AMFI, Amman Mineral, Infratil
- The changes for the KOSPI2 INDEX, KOSDAQ150 Index, CSI300 Index, STAR50 INDEX and a bunch of other onshore China indices were implemented last week.
- The coming week has a lot of rebalance implementations on Friday with the S&P/ASX family and the MVIS family, among others.
- AUM for the Yuanta/P-shares Taiwan Top 50 ETF (0050 TT) has continued to increase with big inflows in the last week.
ECM Weekly (11th June 2023) – Alibaba, Tencent, PDD, Redox, Amman, Kotak, Infratil, Skymark
- Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
- In the IPO space, Australia finally got its IPO counter ticking for the year with Redox (RDX AU).
- On the placement front, Infratil Ltd (IFT NZ) raised to increase its stake in One NZ. While Skymark Airlines (9204 JP) will see a lockup expiry in the coming week.
China Healthcare Weekly (Jun.9) – Pediatric TCM New Policy, Long-Term Money Dislikes A-Share, Clover
- The General Office of National Health Commission issued a notice on further strengthening the management of clinical medication for children. Pediatric TCM is more popular, with decent growth potential.
- Long-Term money choosing to leave A-share isn’t due to geopolitical risks. If outlook isn’t good, the logic of capital’s allocation in A-share isn’t based on promising growth, but on liquidity instead.
- We analyzed key points of Clover Biopharmaceuticals (2197 HK). The Company has entered a vicious cycle. If Clover is abandoned by the market, it will lead to lack of liquidity.
(Mostly) Asia-Pac Weekly Risk Arb Wrap: ENM, Estia Health, Yitai Coal, and Challenger Technologies
- There are 38 – mostly firm, mostly Asia-Pac – transactions currently being discussed and analysed on Smartkarma. Inside is a timetable of upcoming key events for each deal.
- Two new deals were discussed on Smartkarma this week: Chinachem’s Offer Enm Holdings (128 HK); Bain’s non-binding Offer for Chindata Group (CD US).
- Key updates took place for Estia Health (EHE AU), Inner Mongolia Yitai Coal Company Ltd (3948 HK), and Challenger Technologies (CHLG SP).
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
